AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 201 min read$ICCM

IceCure Medical Gains IRB Approval For ChoICE Breast Cancer Cryoablation Study As West Cancer Center

IceCure Medical (ICCM) received IRB approval for its ChoICE study on ProSense cryoablation system for low-risk breast cancer. The study will evaluate the system in patients aged 70+ at West Cancer Center. ProSense is FDA-approved for this use. Earlier trial showed 3.1% local recurrence rate. ICCM stock closed at $2.52, up 0.40% in pre-market.

Original reporting
rttnews.com
Published Aug 20, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ICCM
Bullish
high confidence
Mentioned
$ICCM
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The study aims to generate real‑world evidence, supporting regulatory and payer acceptance.

02

Market read

First‑time IRB clearance provides a new catalyst for ICCM, potentially influencing its share price.

03

What to watch

Reimbursement policies and competition from surgical alternatives could constrain adoption.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

IceCure Medical announced IRB approval for a post‑marketing study of its ProSense system in patients 70+ with low‑risk breast cancer.

Company-level read

Ticker impact

$ICCMBullishHigh confidence
Context

IRB approval for the post‑marketing ChoICE Study of ProSense cryoablation in low‑risk breast cancer.

Expected impact

Modest upside as investors anticipate future sales growth.

Evidence & confidence

Clinical‑trial progress is a key catalyst for biotech stocks; IRB clearance is a fresh, material development.

Market effects

Sector

May boost confidence in minimally invasive breast‑cancer devices and related med‑tech sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low; relevance confined to niche oncology device market.

Counterpoint

What could challenge this read

Study results could be negative, limiting commercial upside despite approval.

Key entities

  • Company
    IceCure Medical Ltd.

    Developer of ProSense cryoablation system.

  • Institution
    West Cancer Center & Research Institute

    IRB granting body for the ChoICE study.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 10
$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

rttnews.com1 min
AUG 20
$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

prnewswire.com2 min
AUG 19
$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.

fool.com3 min
AUG 13
$ICCMMed

IceCure Reports First Half Of 2026 Results With Strong Revenue Growth

IceCure Medical (ICCM) reported six-month results ended June 30, 2026. Revenue rose 45% year over year to $1.8 million from $1.24 million. Gross profit increased to $548,000 from $349,000, helped by higher ProSense system and disposable probe sales. Cash was $12.0 million. The company said U.S. footprint grew 70% and it is advancing its CHoICE post-marketing study.

rttnews.com4 min
AUG 12
$ICCMMed

IceCure Medical Ltd Q2 2026 Earnings Call Summary

IceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.

yahoo.com7 min
AUG 12
$ICCMMed

IceCure Medical Ltd. (ICCM): Financial results for H1 2026

IceCure Medical Ltd. (ICCM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U

SEC EDGAR 6-K3 min